Effect of pomegranate juice consumption on biochemical parameters and complete blood count

EIRINI MANTHOU1,2, KALLOPI GEORGAKOULI1,3, CHARIKLIA K. DELI1,2, AGGELOS SOTIROPoulos1, IOANNIS G. FATOYOURS1,2, DIMITRIOS KOUTERAS4, SERKO HAROUTOUNIAN5, CHRYSOULA MATTHAI05, YIANNIS KOUTEDAKIS1,2,6 and ATHANASIOS Z. JAMURTAS1,2

1Department of Physical Education and Sport Science, University of Thessaly; 2Department of Kinesiology, Institute for Research and Technology Thessaly, Karies, Trikala 42100; 3Department of Nutrition and Dietetics, Technological Educational Institute of Thessaly, Karditsa 43100; 4Department of Biochemistry and Biotechnology, University of Thessaly, Larissa 41221; 5Laboratory of Nutritional Physiology and Feeding, Agricultural University of Athens, Athens 11855, Greece; 6School of Sport, Performing Arts and Leisure, University of Wolverhampton, Walsall, West Midlands WS1 3BD, UK

Received June 9, 2016; Accepted January 20, 2017

DOI: 10.3892/etm.2017.4690

Abstract. Pomegranate has been used therapeutically for centuries. The aim of the present study was to examine the effects of pomegranate juice (PJ) supplementation on complete blood count (CBC), glucose, blood lipids and C-reactive protein (CRP) in healthy subjects. A total of 5 males and 5 females (aged 31.8±6.6 years, weighing 66.2±12.9 kg) were randomly assigned into one of two groups and either consumed 500 ml PJ/day or no PJ for 14 days. Blood samples were obtained from participants prior to and following the experimental period. PJ consumption resulted in a significant increase in red blood cell count (P<0.05), hemoglobin levels (P<0.001) and hematocrit levels (P<0.05). Other CBC parameters, glucose, cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein and CRP levels did not significantly change following PJ consumption. These results indicate that PJ intake for a short period of time may result in increased erythropoiesis or decreased degradation without any significant alterations in factors associated with metabolic health and inflammation in healthy individuals.

Introduction

Pomegranate is a fruit that has been cultivated for centuries and is considered of high nutritional and therapeutic value (1). Its biological and therapeutic properties are primarily attributed to the presence of polyphenols (ellagitannins, flavonoids, phenolic acids, stilbenes, tannins and anthocyanins) (2,3), which are free radical scavenging compounds (4). Pomegranate is also rich in vitamins and minerals (5). Generally, pomegranate juice (PJ) is the greatest contributor to pomegranate ingestion in daily nutrition. Notably, the in vitro antioxidant activity of PJ has been determined to be threefold higher compared with red wine and green tea and is typically more potent than that of other natural juices (6,7).

Based on phytochemical compounds and their activity in PJ, research on the effects of PJ supplementation on health parameters has provided promising results regarding oxidative stress, inflammation and metabolic diseases (8). These studies have been conducted in vitro (9), in animals (10) and humans (11,12). Research conducted on atherosclerotic mice indicated that PJ supplementation reduced the size of atherosclerotic lesions and inhibited disease progression (13-15). Research on patients with cardiovascular disease demonstrated that following PJ supplementation, low density lipoprotein (LDL) levels were reduced (16,17), stress induced ischemia (18) and vascular thickness decreased (19), while positive findings were particularly evident in patients at higher risk of coronary heart disease (20). In healthy individuals, PJ consumption reduced the potential for LDL aggregation, which represents an important step towards formation of foam cells and thus vascular thrombi (13). Furthermore, it has been indicated that PJ intake on a regular basis may affect cholesterol metabolism in macrophages, leading to reduced cellular uptake of oxidized LDL (12). PJ is also able to reduce nitric oxide synthase expression in endothelial cells of coronary vessels (15). In 2001, Das et al (21) examined the effect of pomegranate seed extract ingestion in diabetic rats. The results indicated that there was a significant decrease in glucose levels of ~50%, 12 h after taking the extract, regardless of the dose given (300 and 600 mg/kg). These findings may be the result of an increased absorption of glucose by peripheral tissues, which is associated with the presence of polyphenols in pomegranate and their function (22).
Studies in humans and mice demonstrated that even moderate PJ consumption reduced susceptibility to free radical lipid peroxidation, while it increased resistance to LDL and high density lipoprotein (HDL)-cholesterol oxidation (23). Inhibition of lipid peroxidation with PJ supplementation has been verified in carotid artery stenosis patients (18), type II diabetics (12) and healthy individuals (3). In 2014, Matthaiou et al (3) also determined that glutathione (GSH) levels were increased following two weeks PJ supplementation, indicating that PJ induced beneficial changes in erythrocyte antioxidant concentration. In 2009, Boussetta et al (24) reported that punicic acid, a conjugated unsaturated fatty acid which is derived from the oil of pomegranate seeds, has anti-inflammatory action due to its potential to reduce the activity of neutrophils. Specific tannins in pomegranate also exhibited anti-inflammatory action in mice (25).

Although there have been numerous studies reporting the benefits of the polyphenols contained in PJ on health parameters in those with various diseases, research on healthy humans is scarce. The antioxidant properties of polyphenolic flavonoids may enhance cell resistance to oxidative stress, including red blood cells; however, to the best of our knowledge, the effects of PJ consumption on complete blood counts (CBC) have not been investigated. Therefore, the purpose of the present study was to examine the effects of PJ supplementation on CBC, in addition to glucose, blood lipids and C-reactive protein (CRP) levels in healthy individuals.

Materials and methods

Participants. A total of 10 healthy and recreationally active individuals (5 males and 5 females) aged 31.8±6.6 years and weighing 66.2±12.9 kg were recruited for the current study through flyers and word of mouth in the region of Thessaly, Greece. Power analysis was run using G*Power Data Analysis (Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany) to estimate the required sample size. It was calculated that the necessary sample size was n=10 for statistical power 0.8, P<0.05 and effect size 0.4. Although the majority of previous studies on PJ supplementation have used 14 -18 subjects, the sample size of the present study is enough to support the findings. Inclusion criteria included the absence of any clinical symptom or chronic disease as determined by a health questionnaire. Exclusion criteria included the presence of gastrointestinal or metabolic disease, the taking of any medication (including nutritional supplements such as vitamins, minerals and phytos- terols), smoking, current pregnancy or lactation in women or the following of a specific diet regime. Written informed consent was obtained from all participants when they had been informed of all risks, discomforts and benefits involved with the current study. The procedures were in accordance to the 1975 Helsinki declaration and were approved by the Institutional Review Board of the University of Thessaly (Larissa, Greece).

Study design. During the first visit, participants received information regarding the trial, completed a health and a physical activity questionnaire and signed the consent form. A randomized, counterbalanced, within-subjects experimental design was applied and participants were randomly assigned into two groups (each, n=5). One group consumed 500 ml/day PJ for fourteen days (the experimental group); the other group consumed no PJ for fourteen days (the control group). The four experimental weeks were separated by a one-week washout period. All participants reported to the laboratory at the start and the end of each two-week phase. In each test day at the two-week time point, anthropometric and physiological measurements in addition to blood sampling took place from 8-10 a.m., following an overnight fast. Alcohol consumption and smoking were not allowed for 12 h prior to each test day. Water consumption was ad libitum. All measurements were performed under controlled environmental conditions (the room temperature was 22±2°C, with a relative humidity of 45±4%).

Anthropometric and physiological measurements. Body mass, body fat and hydration level were assessed using leg-to-leg bioelectrical impedance scale (Tanita BF 522 W; Tanita Europe BV, Amsterdam, The Netherlands) while participants were lightly dressed and barefooted. Standing height was measured to the nearest 0.1 cm (Stadiometer 208, Seca GmbH, Hamburg, Germany). Body mass index (BMI) was calculated using the equation BMI=weight (kg)/[height (m)]². Waist and hip circumferences were obtained with measuring tape. Waist to hip ratio (WHR) was calculated using the equation WHR=waist circumference/hip circumference. Blood pressure (BP) was measured with a manual sphygmomanometer (FC-101 Aneroid Sphygmomanometer; Focal Corporation, Tokyo, Japan); the lowest of three readings was recorded. Baseline anthropometric and physiological characteristics of all participants are presented in Table I.

Diet and physical activity. To ensure that diet and/or exercise preceding the trials would not affect biochemical parameters measured in the current study, participants were instructed to refrain from excessive exercise, record meals and physical activity two days prior to the first trial, and follow the same diet and activities for two days prior to each subsequent trial. Each participant was provided with a written set of guidelines and record sheets for recording food intake and physical activity. Diet records were subsequently analyzed using the computerized nutritional analysis system Science Fit Diet 200A (Science Technologies, Athens, Greece; Table II). Participants were instructed to follow their usual habits during the experiment otherwise.

Test food. The juice tested was a commercially available product (CBH-VITOM S.A., Athens, Greece). PJ was provided to the participants in bottles containing 250 ml each and the participants were instructed to consume one in the morning and one in the afternoon (a total of 500 ml per day). Each 250 ml product was prepared from 2.5 squeezed pomegranates. Nutritional values per 100 ml and as percentages of the Recommended Daily Allowance are presented in Table III. The polyphenolic composition of the PJ was measured by Matthaiou et al (3), as the PJ was the same as the one used in the present study. Briefly, the total polyphenolic content was 405.00 mg/l of equivalent gallic acid and the total amount of flavonoid was 12.67 mg/l of equivalent quercetin. PJ also contained different classes of polyphenols as flavonoids, phenolic acids and stilbenes. The concentrations of the
polyphenols contained in the PJ used in the current study were comparable to those identified in previous studies (26). However, total polyphenols in PJ may vary significantly between different pomegranate cultivars (27).

**Blood collection and analyses.** Participants rested in the lab for 30 min prior to blood sample being obtained. Participants were in a seated position when 20 ml blood was drawn from the forearm vein. A portion (1-2 ml) of the blood collected was used to determine the parameters of the CBC measured by an automatic hematology analyzer (Mythic™ 18; Orphee Medical SA, Geneva, Switzerland). Each measurement was performed twice. The remaining blood was centrifuged at 4°C, 1370 x g for 10 min to separate the plasma in a refrigerated centrifuge (Heraeus™ Biogigure Primo; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Then the collected supernatant was transferred to Eppendorf tubes (Sarstedt AG & Co., Numbrecht, Germany). The samples were stored at -80°C and thawed only once prior to analysis. Glucose, total cholesterol, HDL-cholesterol and triglyceride concentrations in plasma were measured using enzymatic kits (Roche Diagnostics, Mannheim, Germany). Table I shows the baseline anthropometric and physiological characteristics of all participants before and after the experimental period.

Table II. Nutritional analysis of the 2-day diet records of all participants, in the experimental and control groups.

<table>
<thead>
<tr>
<th>Component</th>
<th>Pre</th>
<th>Post</th>
<th>Pre</th>
<th>Post</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy, kcal</td>
<td>1771.5±425.1</td>
<td>1765.8±403.0</td>
<td>1737.8±398.2</td>
<td>1783.8±406.4</td>
</tr>
<tr>
<td>Protein, g</td>
<td>74.3±24.1</td>
<td>71.4±25.7</td>
<td>73.8±25.7</td>
<td>73.5±23.3</td>
</tr>
<tr>
<td>Carbohydrate, g</td>
<td>194.2±59.6</td>
<td>193.3±40.4</td>
<td>199.1±68.4</td>
<td>200.7±69.9</td>
</tr>
<tr>
<td>Fat, g</td>
<td>73.3±22.7</td>
<td>75.8±18.1</td>
<td>71.7±21.0</td>
<td>75.1±24.1</td>
</tr>
<tr>
<td>Cholesterol, mg</td>
<td>246.9±143.1</td>
<td>240.7±127.2</td>
<td>250.9±148.1</td>
<td>228.5±110.1</td>
</tr>
<tr>
<td>Fiber, g</td>
<td>15.8±8.4</td>
<td>16.3±8.4</td>
<td>15.5±9.9</td>
<td>15.8±10.2</td>
</tr>
<tr>
<td>Vitamin A, IU</td>
<td>4,264.5±2,193.9</td>
<td>4,443.4±2,895.5</td>
<td>4,513.9±2,917.1</td>
<td>4,527.7±2,854.3</td>
</tr>
<tr>
<td>Vitamin B12, µg</td>
<td>3.5±1.5</td>
<td>3.6±1.7</td>
<td>3.4±2.1</td>
<td>3.6±1.5</td>
</tr>
<tr>
<td>Vitamin B6, mg</td>
<td>1.8±0.5</td>
<td>1.9±0.6</td>
<td>1.7±0.7</td>
<td>1.8±0.5</td>
</tr>
<tr>
<td>Vitamin C, mg</td>
<td>79.3±36.4</td>
<td>77.6±29.0</td>
<td>76.6±33.6</td>
<td>71.5±34.5</td>
</tr>
<tr>
<td>Vitamin D, mg</td>
<td>114.1±81.3</td>
<td>116.3±75.0</td>
<td>105.9±69.7</td>
<td>100.9±56.1</td>
</tr>
<tr>
<td>Vitamin E, mg_RE</td>
<td>8.7±10.5</td>
<td>9.0±9.9</td>
<td>8.6±11.0</td>
<td>8.2±8.9</td>
</tr>
<tr>
<td>Thiamine, mg</td>
<td>2.7±1.4</td>
<td>2.4±1.2</td>
<td>2.2±1.4</td>
<td>2.6±1.3</td>
</tr>
<tr>
<td>Niacin, mg</td>
<td>21.8±7.9</td>
<td>21.0±8.3</td>
<td>19.6±6.9</td>
<td>21.1±6.8</td>
</tr>
<tr>
<td>Pantothenic Acid, mg</td>
<td>11.0±20.6</td>
<td>10.2±17.3</td>
<td>12.1±25.9</td>
<td>10.3±19.1</td>
</tr>
<tr>
<td>Riboflavin, mg</td>
<td>2.4±1.9</td>
<td>2.6±1.7</td>
<td>2.3±1.6</td>
<td>2.2±1.3</td>
</tr>
<tr>
<td>Folate, µg</td>
<td>351.6±106.4</td>
<td>345.5±103.7</td>
<td>346.8±138.8</td>
<td>335.9±87.5</td>
</tr>
<tr>
<td>Iron, mg</td>
<td>14.0±3.2</td>
<td>14.7±4.3</td>
<td>14.7±4.6</td>
<td>14.5±2.7</td>
</tr>
<tr>
<td>Selenium, µg</td>
<td>110.4±33.6</td>
<td>105.0±40.5</td>
<td>106.5±44.7</td>
<td>103.4±39.4</td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation. EG, experimental group; CG, control group; WHR, waist to hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table III. Nutritional values of pomegranate juice per 100 ml and as percentages of the RDA.

<table>
<thead>
<tr>
<th>Component</th>
<th>Per 100 ml</th>
<th>% RDA (250 ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy, kcal</td>
<td>58</td>
<td>7</td>
</tr>
<tr>
<td>Protein, g</td>
<td>0.3</td>
<td>2</td>
</tr>
<tr>
<td>Carbohydrate, g</td>
<td>14.1</td>
<td>12</td>
</tr>
<tr>
<td>Sugars, g</td>
<td>11.6</td>
<td></td>
</tr>
<tr>
<td>Fat, g</td>
<td>0.3</td>
<td>1</td>
</tr>
<tr>
<td>Saturated Fat, g</td>
<td>0.0</td>
<td>0</td>
</tr>
<tr>
<td>Fiber, g</td>
<td>0.1</td>
<td>3</td>
</tr>
<tr>
<td>Salt, mg</td>
<td>0.01</td>
<td>1</td>
</tr>
</tbody>
</table>

RDA, recommended daily allowance.

Results

CBC parameters. No significant results for group or group x time were identified for hemoglobin. However, there were significant differences with respect to time (F1,18=5.12, P<0.05). Pairwise comparison indicated a significant increase (P<0.001) in the concentration of hemoglobin following PJ supplementation, which did not occur in individuals in the control group (Fig. 1B). No significant results for group or group x time were identified for hematocrit. However, there were significant differences with respect to time (F1,18=4.27, P<0.05). Pairwise comparison indicated a significant increase (P<0.05) in hematocrit following PJ supplementation (Fig. 1C).

The remaining CBC parameters prior to and following completion of the two trials are presented in Table IV. In general, these parameters did not change in either group. A significant difference was observed for group x time (F1,17=3.98, P<0.05) in MCHC only. Pairwise comparison demonstrated a significant increase (P<0.05) in MCHC in the control group at the end of the experimental period (Table IV).

Biochemical parameters. Furthermore, PJ supplementation did not significantly alter the concentrations of total cholesterol, HDL, LDL, glucose and triglycerides (Table V). CRP values were not >6 mg/dl, indicating decreased inflammation either at baseline or following the experimental period.

Discussion

The results of the present study demonstrate that PJ consumption of 500 ml/day for two weeks increased the RBC count, hemoglobin concentration and hematocrit in healthy individuals. Other parameters concerning complete blood count, metabolic health or inflammation were not altered in this cohort of individuals. Therefore, PJ intake for a short period of time may result in increased erythropoiesis or prevention of RBC degradation without any significant alterations in factors associated with metabolic health and inflammation in healthy individuals.

RBCs and hemoglobin constitute the transport system of oxygen from the lungs to the tissues. It has been demonstrated that a high concentration of polyphenols may increase the resistance of RBC to oxidative stress (30). Therefore, a potential explanation for the results of the current study is that the increased content of polyphenols in PJ may have prevented RBC destruction due to reduced oxidative stress. Indeed, this hypothesis is further supported by a study reporting higher reduced GSH levels in erythrocytes following 500 ml PJ supplementation every day for two weeks (3). It was noted that this increase may be due to the induction of expression or the catalytic activity of enzymes involved in GSH biosynthesis that are known to be increased by plant polyphenols (31).

Similarly, the participants that consumed PJ exhibited a ~3% increase in hemoglobin by at the end of the two week intervention. This finding is particularly important considering the short period during which participants consumed the juice. It has been determined that flavonoids serve an important role in preventing oxidation of hemoglobin by various factors, such as hypochlorous acid (32). Flavonoids bind to hemoglobin and are able to inhibit oxidation of the hemoglobin molecule by oxidizing agents. In addition to flavonoids, PJ exhibits antioxidant activity...
that is much higher than that of red wine, green tea and other natural juices (4). Antioxidant capacity in erythrocytes has been identified to increase following two weeks of PJ supplementation in healthy individuals (3). Therefore, a potential explanation for the increased hemoglobin levels observed in the current study may be that the phytochemicals contained in PJ juice may have protected hemoglobin from oxidizing agents.

Hematocrit also exhibited a significant increase following two weeks of PJ supplementation. Increasing levels of hematocrit may be due to reduced RBC destruction. The high concentration of antioxidants in PJ is likely to have protected RBC and resulted in their subsequent reduced destruction. However, the measurements completed in the present study cannot confirm which factors caused this change. Therefore, further studies are required to highlight the contribution and importance of each factor, in addition to any potential synergistic effect.

Other parameters of the CBC did not change significantly over the course of PJ supplementation, with the exception of MCHC levels, which were significantly increased in the control group at the end of the experimental period. MCHC is an indicator of the average density of hemoglobin per RBC medium and usually increases in dehydration and hereditary spherocytosis, sickle cell disease and homozygous hemoglobin C disease (33). The change in MCHC was significant only for individuals in the control group. It may be suggested that the increase in MCHC levels is due to dehydration in the control group. However, assessment of hydration status performed through bioelectrical impedance (Table I) did not identify any significant differences over time or between groups. Indeed, this is something that requires further investigation.

Lipid profile was not altered following supplementation of PJ. Previous studies have reported that pomegranate may reduce blood lipid levels and lipid peroxidation (3,34). In diabetic subjects with hyperlipidemia, consumption of PJ concentrate for 8 weeks significantly reduced levels of total cholesterol and LDL (16,17). The absence of any significant changes in the present study may be due to the short duration of supplementation. Also, participants in the current study were individuals with normal lipid levels compared with previous studies where participants had elevated lipid levels (15,16). A previous study has demonstrated that the higher the cardiovascular risk, the greater the changes occurring in risk factors such as cholesterol (20). Individuals in the current study were also normoglycaemic and CRP was within normal levels at baseline. Therefore, this may determine why changes in glucose and CRP were not evident in either group, although a decrease in both parameters has previously been recorded in rats following PJ supplementation (21,24). Finally, studies investigating a greater number of participants would provide more reliable results on the effects of PJ supplementation in various health parameters.

PJ supplementation may result in an increased RBC count, hemoglobin concentration and hematocrit in healthy individuals.

Figure 1. Changes in (A) RBC, (B) hemoglobin and (C) hematocrit following PJ consumption. *P<0.05 vs. Pre of the same group. RBC, red blood cell; PJ, pomegranate juice.
Therefore, PJ supplementation may affect factors involved either in RBC formation and erythropoiesis, or in prevention of RBC degradation. It has been postulated that increased generation of ROS may contribute to the shorter lifespan of RBCs associated with iron-deficiency anemia (35). Therefore, antioxidants such as polyphenols may help counterbalance increased oxidative stress in RBCs, thus preventing their degradation. PJ is a rich source of polyphenols and nutrients and may therefore aid RBCs and other cells to counterbalance oxidative stress. Further research on this topic may reveal if PJ may be used as an adjunctive strategy for the prevention or treatment of certain types of anemia. In conclusion, two weeks of PJ supplementation resulted in an increased RBC count, hemoglobin concentration and hematocrit in healthy individuals. Due to the confirmed functional properties of PJ, further research is required to determine the long-term effects of PJ supplementation on healthy individuals in addition to the effect of different amounts of PJ on various biomedical parameters. Furthermore, it is necessary to investigate the effect of supplementation of PJ on factors affecting RBC formation and erythropoiesis, or prevention of RBC degradation.

Acknowledgements

The authors of the present study wish to thank CBH-VITOM S.A., Athens, Greece, for the provision of the commercial product of pomegranate juice used in the current study.

References


